

Open to Enrollment phase II/III or IV clinical trials (as of July 26, 2016) Study Summary (description of phase)		PI	Primary Coordinator(s)	Sponsor
Acute Coronary Syndromes				
VCU-ART3	Phase II trial to evaluate <u>Anakinra (an IL-1 blocker)</u> on the inflammatory response in <u>acute STEMI</u> .	Antonio Abbate Ben Van Tassell	Leo Buckley	National Institute of Health
Heart Failure				
D-HART2	Phase II trial to evaluate <u>Anakinra (an IL-1 blocker)</u> on exercise capacity in patients with <u>heart failure and preserved EF</u> .	Antonio Abbate Ben Van Tassell	Leo Buckley Justin Canada	National Institute of Health
EMPA-HF	Phase IV study of sodium-glucose co-transporter 2 (SGLT2) inhibition with <u>empagliflozin in systolic heart failure and diabetes</u>	Salvatore Carbone Antonio Abbate	Hayley Billingsley	American Heart Association
PARAGON HF	Phase III Multicenter Clinical Trial of <u>Sacubitril/Valsartan (Entresto)</u> or placebo in patients with <u>heart failure and preserved EF</u> .	Keyur Shah	Laura Cei	Novartis (Industry)
PIONEER HF	Phase III Multicenter Clinical Trial of <u>Sacubitril/Valsartan (Entresto)</u> or placebo in patients with <u>acute decompensated heart failure</u>	Antonio Abbate Ben Van Tassell	Leo Buckley	Novartis (Industry)
Intervention/Structural				
COAPT	Phase III Multicenter Trial of <u>MitraClip device to treat functional mitral regurgitation</u>	Zachary Gertz	Melissa Sears	Abbott (Industry)
PARACHUTE IV	Phase II Percutaneous Ventricular Restoration in Chronic HF due to ischemic heart disease- <u>Parachute device implant</u>	Zachary Gertz	Melissa Sears	Cardiokinetix (Industry)
Electrophysiology				
Cardiac Sarcoidosis Registry	To develop a prospective observational database for the study of <u>cardiac sarcoidosis</u> . (not a clinical trial)	Jordan Kron	Kim Hall	Investigator initiated
AEOIU	Apixaban anticoagulation study – Phase III trial of Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation in Ablation of Atrial Fibrillation.	Kenneth Ellenbogen	Kim Hall	Harvard Clinical Research Institute

RAID	To determine whether <u>ranolazine administration will decrease the likelihood of ventricular tachycardia or ventricular fibrillation requiring antitachycardia pacing or ICD shock</u>	Kenneth Ellenbogen	Kim Hall	Univ of Rochester-National Institute of Health
nMARQ	Phase II trial - The objective will be to demonstrate safety and effectiveness of the nMARQ (circular or crescent) catheter system to <u>Thermocool Navigational Family of catheters in treating subjects with drug-refractory symptomatic paroxysmal atrial fibrillation</u>	Kenneth Ellenbogen	Kim Hall	Biosense Webster, Inc. (Industry)
ENABLE MRI	To confirm safety and effectiveness of the ImageReady MR Conditional Defibrillation System when used in the 1.5T MRI environment for condition of Use labeling (not a treatment study)	Kenneth Ellenbogen	Kim Hall	Boston Scientific
UNTOUCHED	to assess the 18 month incidence of inappropriate shocks in patients implanted with the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) programmed with 200 bpm and 250 bpm, and this will be compared to an Objective Performance Criteria derived from transvenous ICD programming to minimize shocks in the MADIT RIT study.	Gautham Kalahasty	Kim HALL	Cameron Health/Boston Scientific (Industry)
CABANA	Phase III trial -Primary Aim is to test the treatment strategy of <u>percutaneous left atrial catheter ablation for eliminating atrial fibrillation is superior to current state of the art therapy</u> with either rate control or rhythm control drugs for reducing total mortality in patients with untreated or undertreated atrial fibrillation.	Kenneth Ellenbogen	Kim Hall	Mayo Clinic Rochester-NIH
AdaptResponse	Phase III trial - To test that <u>AdaptivCRT reduces incidence of combined endpoint of all cause mortality and intervention for heart failure decompensation</u> , compared to standard CRT therapy, in patients with CRT indication, LBBB and normal AV conduction. Intervention for heart failure decompensation (HF events) is defined as an event requiring invasive intervention	Richard Shepard	Kim Hall	Medtronic (Industry)
VENUS-AF	Phase II trial - VENUS AF- Vein of Marshall infusion in untreated persistent AF is to assess the role of VOM ethanol infusion in de novo catheter ablation of persistent AF. <u>MARS-AF- Vein Of Marshall Ethanol infusion after a failed conventional ablation of persistent AF.</u>	Kenneth Ellenbogen	Kim Hall	Houston Methodist Research Institute-NIH
DEEP	Phase II- The purpose of this clinical study is to evaluate how safe and effective a less invasive cardiac surgery treating patients with persistent AF. This procedure treats both the outside of the heart (epicardium) using the AtriCure Bipolar System followed by treating the inside of the heart (endocardium) using a catheter ablation procedure.	Vigneshwar Kasirajan Kenneth Ellenbogen	Kim Hall	Atricure (Industry)
Cardiothoracic Surgery				
70 CC	Phase III - SYNCARDIA 70cc total artificial heart (TAH-t) FOR DESTINATION THERAPY (DT)	Tang	Judy Katzen	SynCardia
50 CC	Phase III - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant (BTT)	Tang	Judy Katzen	SynCardia
Momentum III	Phase III - to evaluate the safety and effectiveness of the HeartMate 3™ Left Ventricular Assist System (HeartMate 3) and to compare it to the HeartMate II Left Ventricular Assist System.	Kasirajan	Jinfeng (Jin) Han	HeartMate